Agios Pharm Stock Today
| AGIO Stock | USD 58.66 0.44 0.74% |
Performance11 of 100
| Odds Of DistressLess than 8
|
Agios Pharm is selling at 58.66 as of the 28th of November 2024; that is 0.74 percent decrease since the beginning of the trading day. The stock's open price was 59.1. Agios Pharm has only a 8 % chance of going through financial distress over the next few years and had a good performance during the last 90 days. Note, on February 15, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Agios Pharm's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of July 2013 | Category Healthcare | Classification Health Care |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. The company has 57.03 M outstanding shares of which 4.34 M shares are presently shorted by private and institutional investors with about 6.65 trading days to cover. More on Agios Pharm
Moving together with Agios Stock
| 0.65 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Agios Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Agios Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAgios Pharm can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Agios Pharm's financial leverage. It provides some insight into what part of Agios Pharm's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Agios Pharm (AGIO) is traded on NASDAQ Exchange in USA. It is located in 88 Sidney Street, Cambridge, MA, United States, 02139 and employs 383 people. Agios Pharm is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.37 B. Agios Pharm conducts business under Biotechnology sector and is part of Health Care industry. The entity has 57.03 M outstanding shares of which 4.34 M shares are presently shorted by private and institutional investors with about 6.65 trading days to cover.
Agios Pharm currently holds about 819.31 M in cash with (296.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95.
Check Agios Pharm Probability Of Bankruptcy
Ownership AllocationThe majority of Agios Pharm outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Agios Pharm to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Agios Pharm. Please pay attention to any change in the institutional holdings of Agios Pharm as this could imply that something significant has changed or is about to change at the company. On February 15, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Agios Pharm's common stock.
Check Agios Ownership Details
Agios Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.2 M | |
| Bvf Inc | 2024-09-30 | 1.2 M | |
| Marshall Wace Asset Management Ltd | 2024-06-30 | 1.1 M | |
| Rock Springs Capital Management Lp | 2024-06-30 | 1 M | |
| Bnp Paribas Investment Partners Sa | 2024-06-30 | 911.2 K | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 882.7 K | |
| Fisher Asset Management, Llc | 2024-09-30 | 855.3 K | |
| Deutsche Bank Ag | 2024-06-30 | 662.2 K | |
| Gw&k Investment Management, Llc | 2024-09-30 | 630.9 K | |
| Farallon Capital Management, L.l.c. | 2024-09-30 | 5.7 M | |
| Vanguard Group Inc | 2024-09-30 | 5.5 M |
Agios Pharm Historical Income Statement
Agios Stock Against Markets
Agios Pharm Corporate Management
| DSc FRSC | CoFounder Board | Profile | |
| Dr DACVP | Consultant | Profile | |
| Sarah MD | Chief Development | Profile | |
| James Burns | Corporate Officer | Profile | |
| Clive Patience | Chief Officer | Profile | |
| ShinSan Su | CoFounder Board | Profile | |
| Brian MBA | CEO Director | Profile |
Already Invested in Agios Pharm?
The danger of trading Agios Pharm is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Agios Pharm is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Agios Pharm. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Agios Pharm is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.